Preladenant_LCMS_07680_MedChemExpress
3_种常用碳青霉烯类抗生素血药浓度UPLC-MS
3种常用碳青霉烯类抗生素血药浓度UPLC-MS/MS检测方法的建立Δ秦怡1＊，张瑞霞2，吕雅瑶2，翁莉莉1，张弋2 #（1.天津医科大学一中心临床学院，天津 300192；2.天津市第一中心医院药学部，天津 300192）中图分类号 R917；R978.1文献标志码 A 文章编号 1001-0408（2024）03-0343-05DOI 10.6039/j.issn.1001-0408.2024.03.14摘要目的建立3种临床常用碳青霉烯类抗生素——厄他培南（ETP）、亚胺培南（IPM）、美罗培南（MEM）血药浓度检测的超高效液相色谱-质谱联用（UPLC-MS/MS）法。
方法血浆样品经甲醇沉淀蛋白后，以3种抗生素的稳定性同位素（ETP-D4、IPM-D4、MEM-D6）为内标，采用ACQUITY UPLC BEH C18（2.1 mm×50 mm，1.7μm）色谱柱分离；流动相为98%乙腈+2%水+0.1%甲酸和98%水+2%乙腈+0.1%甲酸，梯度洗脱；流速为0.3 mL/min；柱温为40 ℃；采用正离子、多反应监测模式进行扫描分析。
结果该方法专属性良好，在ETP、IPM、MEM 0.2～200、0.1～100、0.1～100μg/mL范围内线性良好（r2≥0.993），批内、批间精密度和准确度良好（RE均≤5.14%，RSD均≤11.15%），基质效应、提取回收率较一致（RSD≤12.99%）。
结论本实验建立了一种可以同时定量ETP、IPM、MEM血药浓度的UPLC-MS/MS法，该方法样品前处理简单、检测时间短、所需样品量少，可满足临床需求。
关键词碳青霉烯类抗生素；超高效液相色谱-质谱联用；血药浓度；厄他培南；亚胺培南；美罗培南Establishment of UPLC-MS/MS method for the determination of plasma concentration of three common carbapenem antibioticsQIN Yi1，ZHANG Ruixia2，LYU Yayao2，WENG Lili1，ZHANG Yi2（1. First Central Clinical College of Tianjin Medical University，Tianjin 300192，China；2. Dept. of Pharmacy，Tianjin First Central Clinical Hospital，Tianjin 300192， China）ABSTRACT OBJECTIVE To establish a UPLC-MS/MS method for the determination of plasma concentration of three carbapenem antibiotics，i.e. ertapenem （ETP），imipenem （IPM）and meropenem （MEM）.METHODS After protein precipitation with methanol，the plasma samples were separated by ACQUITY UPLC BEH C18column （2.1mm×50mm，1.7μm）using stable isotopes of three antibiotics （ETP-D4，IPM-D4，MEM-D6）as the internal standard. The mobile phases were 98%acetonitrile +2% water +0.1%formic acid and 98%water +2%acetonitrile +0.1%formic acid，by gradient elution. The flow rate was 0.3mL/min and the column temperature was 40 ℃. Scanning analysis was performed in the positive ion and multiple reaction monitoring mode. RESULTS The method had good specificity，good linearity （r2≥0.993）in the range of 0.2-200，0.1-100and 0.1-100μg/mL of ETP，IPM and MEM，and good intra-batch and inter-batch precision and accuracy （all RE≤5.14%，all RSD≤11.15%），the matrix effect and extraction recovery were consistent （RSD≤12.99%）. CONCLUSIONS This study establishes the UPLC-MS/MS method to simultaneously quantify the plasma concentration of ETP，IPM and MEM. The method has the advantages of simple pretreatment， short detection time and small sample quantity to meet clinical requirement.KEYWORDS carbapenem antibiotics； UPLC-MS/MS； plasma concentration； ertapenem； imipenem； meropenem碳青霉烯类抗生素具有抗菌谱广、抗菌活性强、耐药率低的特点，已成为治疗重症感染的主要选择。
A-867744_SDS_MedChemExpress
Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:May-24-2017Print Date:May-24-20171. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :A-867744Catalog No. :HY-12149CAS No. :1000279-69-51.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms: A 867744; A867744Formula:C20H19ClN2O3SMolecular Weight:402.89CAS No. :1000279-69-54. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Powder-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance Light yellow to yellow (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2017 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
柱前衍生高效液相色谱-荧光检测法测定血浆中同型半胱氨酸
柱前衍生高效液相色谱-荧光检测法测定血浆中同型半胱氨酸唐秀芳;甄乾娜;樊子勉;冯成亚;丁敏【摘要】A precolumn derivatization-high performance liquid chromatographic method for the determination of homocysteine (Hey) in plasma was established. Tris (2-carboxyethyl) phos-phine hydrochloride (TCEP) and N-( 1-pyrenyl) maleimide (NPM) were used as the reduced reagent and derivatization reagent, respectively. The separation was carried out on an Agilent Hypersil C-18 column (250 mm x4. 0 mm, 5μm) in gradient elution mode. The mobile phase consisted of A (15 mmoI/L sodium acetate solution), B (acetonitrile) and C (300 mL water containing 1 mL acetic acid and 1 mL phosphoric acid). The eluate was monitored by the fluorescence detector at an excitation wavelength of 330 nm and an emission wavelength of 380 nm. The mean recovery of Hey was (102.08±4.94)%. The linear range was from 0.500 μmol/L to 100μmol/L, with a detection limit of 0. 016μmol/L. The intra-day and inter-day relative standard deviations (RSDs) for Hey were less than 5%. Seven plasma samples of patients with hypertension and seven plasma samples of healthy controls were tested, and the results demonstrated that the Hey in the plasma from the hypertension group was significantly different from that of the control group (p < 0. 05). The developed method is simple, fast, accurate, and suitable for clinical measurement.%建立了一种柱前衍生高效液相色谱-荧光检测法用于测定血浆中同型半胱氨酸(Hcy).使用三(2-羧乙基)膦盐酸盐(TCEP)为还原剂,N-(1-芘)马来酰亚胺(NPM)为衍生剂进行样品预处理,AgilentHypersil C-18柱(250mm ×4.0 mm,5μm)进行分离,流动相为15 mmol/L醋酸钠-乙腈-混合酸(300 mL水中含1mL醋酸和1mL磷酸)混合溶液,采用梯度洗脱,荧光检测激发波长为330nm,发射波长为380 nm.Hcy的回收率为(102.08±4.94)％.线性范围为0.500～100μmol/L,检出限(以信噪比为3计)为0.016μmol/L.日内与日间相对标准偏差均小于5％.利用该方法对7例高血压患者和7例健康志愿者的血浆进行了测定,结果表明两组间的Hcy含量存在显著的差异(p＜0.05).本方法简单、快速、灵敏、特异,适用于血浆Hcy的临床定量测定.【期刊名称】《色谱》【年(卷),期】2012(030)006【总页数】5页(P613-617)【关键词】高效液相色谱;荧光检测;同型半胱氨酸;血浆【作者】唐秀芳;甄乾娜;樊子勉;冯成亚;丁敏【作者单位】重庆医科大学检验医学院,临床检验诊断学教育部重点实验室,重庆400016;重庆医科大学附属第一医院内分泌内科,重庆400016;重庆医科大学检验医学院,临床检验诊断学教育部重点实验室,重庆400016;重庆医科大学检验医学院,临床检验诊断学教育部重点实验室,重庆400016;重庆医科大学检验医学院,临床检验诊断学教育部重点实验室,重庆400016【正文语种】中文【中图分类】O658同型半胱氨酸(homocysteine，Hcy)是一种含硫氨基酸，为甲硫氨酸(methionine，Met)代谢过程中的重要中间产物。
AR-A014418_DataSheet_MedChemExpress
Inhibitors, Agonists, Screening Libraries Data SheetBIOLOGICAL ACTIVITY:AR–A014418 is a selective and effective GSK3β inhibitor with an IC 50 value of 104 nM, and has no significant inhibition on 26 other kinases.IC50 & Target: IC50: 104 nM (GSK3β)In Vitro: AR–A014418 inhibits tau phosphorylation at a GSK3–specific site (Ser–396) in 3T3 fibroblasts expressing human four–repeat tau protein with IC 50 of 2.7 μM, and protects cultured N2A cells from death induced by blocking PI3K/PKB pathway. In hippocampal slices, AR–A014418 inhibits neurodegeneration mediated by beta–amyloid peptide [1]. While in NGP and SH–5Y–SY cells,AR–A014418 reduces neuroendocrine markers and suppresses neuroblastoma cell growth [2].In Vivo: In ALS mouse model with the G93A mutant human SOD1, AR–A014418 (0–4 mg/kg, i.p.) delays the onset of symptoms,improves motor activity, slows down disease progression, and postpons the endpoint of the disease [3]. In addition, AR–A014418produces inhibition effect on acetic acid– and formalin–induced nociception in mice by modulating NMDA and metabotropic receptor signaling as well as TNF–α and IL–1β transmission in the spinal cord [4].PROTOCOL (Extracted from published papers and Only for reference)Kinase Assay:[1]The competition experiments are carried out in duplicate with 10 concentrations of the inhibitor inclear–bottomed microtiter plates. The biotinylated peptide substrate, biotin–AAEELDSRAGS(PO3H2)PQL, is added at a final concentration of 2 μM in an assay buffer containing 6 milliunits of recombinant human GSK3 (equal mix of both α and β), 12mM MOPS, pH 7.0, 0.3 mM EDTA, 0.01% β–mercaptoethanol, 0.004% Brij 35, 0.5% glycerol, and 0.5 μg of bovine serumalbumin/25 μL and preincubated for 10–15 min. The reaction is initiated by the addition of 0.04 μCi of [γ–33P]ATP and unlabeled ATP in 50 mM Mg(Ac)2 to a final concentration of 1 μM ATP and assay volume of 25 μL. Blank controls without peptide substrate are used.After incubation for 20 min at room temperature, each reaction is terminated by the addition of 25 μL of stop solution containing 5mM EDTA, 50 μM ATP, 0.1% Triton X–100, and 0.25 mg of streptavidin–coated SPA beads corresponding to appr 35 pmol of binding capacity. After 6 h the radioactivity is determined in a liquid scintillation counter. Inhibition curves are analyzed by non–linear regression using GraphPad Prism.Cell Assay: AR–A014418 is dissolved in DMSO.[1]Cell viability is assessed by calcein/propidium iodide uptake. Calcein AM is taken up and cleaved by esterases present within living cells, yielding yellowish–green fluorescence, whereas PI is only taken up by dead cells,which become orange–red fluorescent. In brief, N2A cells are cultured for 2 days in vitro and then treated with 50 μM LY–294002 in the presence of AR–A014418 or vehicle (DMSO) for 24 h. Subsequently, N2A cells are incubated for 30 min with 2 μM PI and 1 μM calcein–AM. The cultures are then rinsed three times with Hanks' buffered saline solution containing 2 mM CaCl 2, and the cells are visualized by fluorescence microscopy using a Zeiss Axiovert 135 microscope. Three fields (selected at random) are analyzed per well (appr 300 cells/field) in at least three different experiments. Cell death is expressed as percentage of PI–positive cells from the total number of cells. In every experiment, specific cell death is obtained after subtracting the number of dead cells present inProduct Name:AR–A014418Cat. No.:HY-10512CAS No.:487021-52-3Molecular Formula:C 12H 12N 4O 4S Molecular Weight:308.31Target:GSK–3; GSK–3Pathway:Stem Cell/Wnt; PI3K/Akt/mTOR Solubility:10 mM in DMSOvehicle–treated cultures.Animal Administration: AR–A014418 is formulated in normal saline.[3]First, to examine the effects of GSK–3 inhibition on the clinical symptoms, life span, and motor behavior function of ALS, 56 Tg mice are divided into four groups. In each group, 0.5 mL of normal saline is mixed with either 0 μg (control group), 1 μg (group A), 2 μg (group B) or 4 μg (group C) of AR–A014418 per gram of mouse, and injected intraperitoneally into 14 animals per group 5 days a week beginning 60 days after birth. The mice are sacrificed at the endpoint described below.References:[1]. Bhat R, Xue Y, Berg S, Structural insights and biological effects of glycogen synthase kinase 3–specific inhibitor AR–A014418. J Biol Chem. 2003 Nov 14; 278(46):45937–45.[2]. Carter YM, et al. Specific glycogen synthase kinase–3 inhibition reduces neuroendocrine markers and suppresses neuroblastoma cell growth. Cancer Biol Ther. 2014 May;15(5):510–5.[3]. Koh SH, et al. Inhibition of glycogen synthase kinase–3 suppresses the onset of symptoms and disease progression of G93A–SOD1 mouse model of ALS. Exp Neurol. 2007 Jun;205(2):336–46.[4]. Martins DF, et al. The antinociceptive effects of AR–A014418, a selective inhibitor of glycogen synthase kinase–3 beta, in mice. J Pain. 2011 Mar;12(3):315–22.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
【实验】转基因植物产品检测实验室一览
【关键字】实验转基因植物产品检测实验室一览其他设备：细胞融合仪、核酸提取仪、紫外分光光度计、核酸蛋白检测仪磁力搅拌机杂交仪、-30℃低温冰箱、超低温冰箱、漩涡混合器、超声波细胞粉碎仪、自动恒温酶标。
7 操作步骤7.1 抽样参照 NY/T672 转基因植物及其产品检测通用要求和NY/T673 转基因植物及其产品检测抽样。
7.2 制样参照 NY/T672 转基因植物及其产品检测通用要求和NY/T673 转基因植物及其产品检测抽样（按照GB 5491中四分法制备样品进行送检）。
7.3 DNA模板的制备a称取200-400 mg试样，在液氮中磨碎，装入已经用液氮预冷的1.5 ml离心管中。
b加入1ml预冷至4 ℃的抽提液，剧烈摇动混匀后，在冰上静置5分钟，用13 000 r/min离心机，4 ℃离心15 min，弃去上清液。
c加入600 μl 预热到65 ℃的抽提裂解液，用玻棒搅拌上下颠倒充分混匀，在65 ℃的水浴锅中裂解40 min。
d用13 000 r/min离心机室温离心10 min，将上清液转至另一离心管中，加入5 μl RNase A （10 mg/ml），37 ℃水浴30 min。
e分别用等体积苯酚：氯仿：异戊醇（25：24：1）和氯仿：异戊醇（24：1）各抽提一次。
f用13 000 r/min离心机室温离心10 min，将上清转至另一离心管中。
加入2/3体积异丙醇，1/10 体积3M乙酸钠（pH 5.6），-20 ℃放置2-3 h，充分沉淀DNA。
g13 000 r/min，4 ℃离心15 min，用70%乙醇洗沉淀一次，倒出乙醇，晾干DNA。
加入50 μl TE（pH8.0）溶解DNA。
h把DNA溶液浓度用重蒸馏水调制为100ng/μl，储存于-20 ℃备用。
注意：I 1 g试样（如棉花种子）提取的DNA量应不小于200 μg。
II DNA的OD260/OD280的比值应在1.8左右，且OD260的值应在曲线的最高峰。
佩兰乙醇提取物对结肠癌RKO细胞的抑制作用研究
实验 研 究
佩 兰 乙醇 提取 物对 结肠 癌 ＲＫＯ细 胞 的 抑 制 作 用 研 究
【摘 要 】 目的 ：研究佩兰乙醇提取 物对结 肠癌 ＲＫＯ细胞 的体外 抗肿 瘤作用 。方法 ：ＳＲＢ法 检测 细胞 态的变化 ；免疫 印迹 法检 测结肠癌 ＲＫＯ细胞 中 Ｂｃｌ一２蛋 白、Ｃｌｅａｖｅｄ Ｃａｓｐａｓｅ一３蛋 白的表 达情
况 。结果 ：佩兰乙醇提取物在 ３ ｇ／ｍＬ时对结肠癌 ＲＫＯ细胞 已具有抑 制生长作 用 ，而且随着浓度 的增加其抑 制率也逐 渐
Ｃａｎｃｅｒ ＲＫ Ｏ Ｃｅｌｌｓ Ｐｒｏｌｉｆｅｒａｔｉｏｎ ｉｎ Ｖ ｉｔｒｏ
ＪＩＡＮＧ Ｎｉａｎ ＇ ＳＯＮＧ ＣｈａｎｇＷｅｉ ’ ＹＵ ＣｈａｎｇＹａｎ ，。 ＱＩＮ Ｙｉｎｇ ’。 ＷＥＩ ＬｉｎｇＫａｉ ＬＩＵ Ｙｕｎ ｆ。
１． Ｍｅｄｉｃａｌ ａｎｄ Ｂｉｏｌｏｇｉｃａｌ Ｒｅｓｅａｒｃｈ Ｃｅｎｔｅｒ，Ｚｕｎｙｉ Ｍｅｄｉｃａｌ Ｕｎｉｖｅｒｓｉｔｙ，Ｚｕｎｙｉ ５６３０００， Ｃｈｉｎａ； ２． Ｇｕｉｚｈｏｕ Ｐｒｏｖｉｎｃｉａｌ Ｃｏｌｌｅｇｅ—ｂａｓｅｄ Ｋｅｙ Ｌａｂ ｆｏｒ Ｔｕｍｏｒ Ｐｒｅｖｅｎｔｉｏｎ ａｎｄ Ｔｒｅａｔｍｅｎｔ ｗｉｔｈ Ｄｉｓｔｉｎｃｔｉｖｅ Ｍｅｄｉｃｉｎｅｓ，Ｚｕｎｙｉ ５６３０００，Ｃｈｉｎａ；
ｔｅｃｔｅｄ ｂｙ Ｗｅｓｔｅｒｎ ｂｌｏｔ．Ｒｅｓｕｌｔｓ Ｔｈｅ ｇｒｏｗｔｈ ｏｆ ＲＫＯ ｃｅｌｌｓ ｗｅｒｅ ｉｎｈｉｂｉｔｅｄ ｏｆ ｅｔｈａ ｎ ｏｌ ｅｘｔｒａｃｔ ｆｒｏｍ Ｅｕｐａｔｏｒｉｕｍ ｆｏｒｔｕｎｅｉ Ｔｕｒｃｚ ａｔ ｔｈｅ ｃｏｎ—
胃泌素释放肽前体定量测定试剂盒、其制备方法及检测方法[发明专利]
![胃泌素释放肽前体定量测定试剂盒、其制备方法及检测方法[发明专利]](https://img.taocdn.com/s3/m/26f3b31cf61fb7360a4c651b.png)
专利名称：胃泌素释放肽前体定量测定试剂盒、其制备方法及检测方法
专利类型：发明专利
发明人：奚伟红,朱丹丹,王京,高淑舫,陈美
申请号：CN201410297442.7
申请日：20140627
公开号：CN104089949A
公开日：
20141008
专利内容由知识产权出版社提供
摘要：本发明涉及一种胃泌素释放肽前体（ProGRP）定量测定试剂盒及其检测方法，包括磁分离试剂的制备、酶反应物的制备、反应增强剂的配制、校准品稀释液的配制、校准品和质控品的配制、清洗浓缩液的配制和底物溶液的配制七个步骤。
本发明胃泌素释放肽前体（ProGRP）定量测定试剂盒及其检测方法具有较高的灵敏度和特异性，更短的获得检测结果的时间和更简便的操作方式，还能区分小细胞肺癌（SCLC）和非小细胞肺癌（NSCLC），对肺癌的早期诊断具有重要意义。
申请人：江苏福隆生物技术有限公司
地址：214434 江苏省无锡市江阴市城东街道东盛西路78号
国籍：CN
代理机构：江阴市同盛专利事务所(普通合伙)
更多信息请下载全文后查看。